Idebenone
11 benefits mapped to clinical evidence across supplements.
Dose per serving from research
18 study groups in 14 studies say how much Idebenone participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 44% of 18 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mg or less | 1 |
| 50 mg to 100 mg | 3 |
| 100 mg to 250 mg | 0 |
| 250 mg to 500 mg | 8 |
| 500 mg to 1 g | 6 |
Benefit Evidence
Fewer lung complications
-67% incidence
Shorter illness, less antibiotics
Research sources
Memory (7)
- Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
PubMed ID: 9850939
Large 2‑year trial with dose‑related, sustained improvements in cognitive measures (highest support for memory).
- Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial
PubMed ID: 15374367
Elderly subjects with cognitive decline showed superior performance on memory tests vs oxiracetam (active comparator).
- Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia
PubMed ID: 15374363
Well-designed RCT (120 days) showed significant improvements on memory tests (Randt Memory Test, MMSE) vs placebo.
- Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial
PubMed ID: 15374366
Randomized DB-PC trial in multi-infarct dementia reported significant memory improvement vs placebo over 90 days.
- Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study
PubMed ID: 11819153
More responders vs tacrine on composite efficacy index (moderate memory support).
- A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
PubMed ID: 9267856
Large multicenter RCT showed improvements on ADAS‑Cog and global cognitive scales (strong memory signal).
- Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type
PubMed ID: 7988944
RCT in Alzheimer‑type dementia reported significant short‑term memory improvement vs placebo.
Mental clarity (7)
- A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
PubMed ID: 9267856
Large AD trial showed improved cognitive scores (likely translates to clearer thinking).
- Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
PubMed ID: 9850939
Two‑year, dose‑related sustained cognitive improvements in AD indicate meaningful effect on mental clarity.
- Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study
PubMed ID: 11819153
Head‑to‑head vs tacrine showed more clinical improvers (moderate signal for clarity).
- Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial
PubMed ID: 15374366
Randomized DB-PC trial in multi-infarct dementia reported improved attention and orientation, consistent with better mental clarity.
- Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type
PubMed ID: 7988944
Small RCT in Alzheimer patients reported short‑term improvements in memory and attention (supports subjective clarity).
- Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia
PubMed ID: 15374363
Multicenter RCT showed improvements in attention and overall cognition vs placebo, supporting clearer thinking.
- Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial
PubMed ID: 15374367
Active-comparator trial found superior cognitive performance vs oxiracetam, suggesting some benefit for clarity though no placebo arm.
Brain health (6)
- Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial
PubMed ID: 15374366
Cognitive and orientation benefits in multi-infarct dementia suggest potential neuroprotective effects, though no direct biomarker evidence was reported.
- Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
PubMed ID: 9850939
Two‑year AD trial with dose‑dependent sustained cognitive and functional benefits suggests possible neuroprotection.
- A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
PubMed ID: 9267856
Large multicenter AD trial improved cognitive outcomes, consistent with brain protective effects.
- Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type
PubMed ID: 7988944
Short‑term improvements in memory/attention in AD support temporary brain functional protection.
- Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial
PubMed ID: 15374367
Superior cognitive outcomes vs oxiracetam indicate possible brain benefit, but lack of placebo limits inference on protection.
- Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia
PubMed ID: 15374363
Improvements in overall cognition in a placebo-controlled trial imply beneficial effects on brain function in patients with cognitive decline.
Focus & concentration (5)
- A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
PubMed ID: 9267856
Broad cognitive improvement in large AD study likely includes attentional benefits.
- Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia
PubMed ID: 15374363
RCT reported significant attention improvements (Toulouse Piéron Test, Token Test) vs placebo.
- Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type
PubMed ID: 7988944
Reported attention improvements in small AD RCT (direct evidence for focus).
- Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial
PubMed ID: 15374366
Trial documented improved attention vs placebo in multi-infarct dementia patients.
- Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
PubMed ID: 9850939
Sustained cognitive benefit in AD patients suggests possible focus improvement.
Energy & Fatigue (3)
- Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
PubMed ID: 25907158
DELOS respiratory preservation in DMD reflects maintained muscle energetics/mitochondrial support in respiratory muscles.
- Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
PubMed ID: 9850939
Long‑term cognitive and functional benefits in AD are compatible with improved neuronal cellular energy over time.
- Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial
PubMed ID: 17826341
Dose‑related neurologic improvements in ambulant FRDA children suggest improved cellular/mitochondrial function despite unchanged oxidative marker.
Eye health (3)
- Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy
PubMed ID: 23388409
Long‑term follow‑up showed visual benefit persisted months–years after stopping idebenone (strong vision support).
- Effects of idebenone on color vision in patients with leber hereditary optic neuropathy
PubMed ID: 23263355
RHODOS subgroup: statistically significant preservation/improvement of tritan (blue‑yellow) colour contrast vs placebo.
- A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy
PubMed ID: 21788663
Randomized LHON trial: significant secondary and subgroup visual benefits and colour contrast improvements.
Healthy aging (2)
- Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
PubMed ID: 9850939
Sustained, dose‑related cognitive and functional benefits over two years in AD are suggestive of slowing disease‑related aging processes in brain.
- A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
PubMed ID: 9267856
Positive cognitive effects in AD indicate potential to influence age‑related cognitive decline.
Vitality (2)
- Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
PubMed ID: 9850939
Sustained cognitive and functional improvements in AD imply better overall vitality in that population.
- Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
PubMed ID: 25907158
DELOS showed clinically relevant preservation of respiratory function in DMD, likely improving day‑to‑day vitality.
Endurance (2)
- Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
PubMed ID: 25907158
DELOS phase‑3: statistically significant preservation of PEF%p and FVC/FEV1 attenuation — strong evidence for maintained respiratory endurance in DMD.
- Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy
PubMed ID: 27571420
Preservation of inspiratory muscle function in DELOS secondary analyses supports improved/maintained endurance.
Cell health (2)
- Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial
PubMed ID: 17826341
FRDA pediatric trial showed dose‑related neurologic improvements in ambulant patients — consistent with mitochondrial mechanism despite biomarker limits.
- Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study
PubMed ID: 21779958
Open‑label extension in FRDA found stabilization/improvement at higher idebenone doses over 12–18 months (supports mitochondrial benefit).
Illness recovery (1)
- Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy
PubMed ID: 27238057
DELOS post‑hoc: fewer/shorter bronchopulmonary events and less antibiotic use (faster clinical recovery from respiratory events).
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Idebenone
Search all1 product whose verified label declares Idebenone — not every bottle that mentions it in a title.